Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shannon L Maude

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Clinical Advances in Hematology & Oncology : H&O|December 14, 2018
Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemiaShannon L Maude
Blood|November 25, 2017
CAR emissions: cytokines tell the storyShannon L Maude
Current Opinion in Pediatrics|November 15, 2016
Future directions in chimeric antigen receptor T cell therapyShannon L Maude
Blood|July 15, 2017
CART attackVinodh Pillai, Shannon L Maude
Hematology. American Society of Hematology. Education Program|December 4, 2020
CAR T cells vs allogeneic HSCT for poor-risk ALLCaroline Diorio, Shannon L Maude
Hemasphere|November 15, 2019
Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALLAmanda M DiNofia, Shannon L Maude
Current Opinion in Pediatrics|November 28, 2017
New developments in immunotherapy for pediatric leukemiaJessica B Foster, Shannon L Maude
Hematology. American Society of Hematology. Education Program|December 5, 2025
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?Amanda M Li, Shannon L Maude
Cancer Research|February 12, 2005
Cdk inhibition in human cells compromises chk1 function and activates a DNA damage responseShannon L Maude, Greg H Enders
Hematology. American Society of Hematology. Education Program|December 4, 2020
What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?Aimee C Talleur, Shannon L Maude
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Clinical Advances in Hematology & Oncology : H&O|December 14, 2018
Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemiaShannon L Maude
Blood|November 25, 2017
CAR emissions: cytokines tell the storyShannon L Maude
Current Opinion in Pediatrics|November 15, 2016
Future directions in chimeric antigen receptor T cell therapyShannon L Maude
Blood|July 15, 2017
CART attackVinodh Pillai, Shannon L Maude
Hematology. American Society of Hematology. Education Program|December 4, 2020
CAR T cells vs allogeneic HSCT for poor-risk ALLCaroline Diorio, Shannon L Maude
Hemasphere|November 15, 2019
Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALLAmanda M DiNofia, Shannon L Maude
Current Opinion in Pediatrics|November 28, 2017
New developments in immunotherapy for pediatric leukemiaJessica B Foster, Shannon L Maude
Hematology. American Society of Hematology. Education Program|December 5, 2025
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?Amanda M Li, Shannon L Maude
Cancer Research|February 12, 2005
Cdk inhibition in human cells compromises chk1 function and activates a DNA damage responseShannon L Maude, Greg H Enders
Hematology. American Society of Hematology. Education Program|December 4, 2020
What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?Aimee C Talleur, Shannon L Maude
Pageof 9